drugset

drugset / Trial / NCT01417143

Dovitinib in Adenoid Cystic Carcinoma

NCT01417143 ↗

Phase 2 Completed 33 enrolled Seoul National University Hospital

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).

Timeline

Start: 2011-09
Primary completion: 2013-12
Completion: 2014-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dovitinib	Small molecule	500 mg	Oral

Indications